PAK1 silencing is synthetic lethal with CDK4/6 inhibition in gastric cancer cells via regulating PDK1 expression

[1]  K. Jain.  Basic Aspects , 2020, Textbook of Personalized Medicine.

[2]  L. Lundell,et al.  Improvements in esophageal and gastric cancer care in Sweden-population-based results 2007–2016 from a national quality register , 2019, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[3]  C. Murphy.  The Role of CDK4/6 Inhibitors in Breast Cancer , 2019, Current Treatment Options in Oncology.

[4]  R. Cabeza,et al.  Present and Future , 2008 .

[5]  Dong-mei Zhao,et al.  Targeting PAK1 with the Small Molecule Drug AK963/40708899 Suppresses Gastric Cancer Cell Proliferation and Invasion by Downregulation of PAK1 Activity and PAK1‐Related Signaling Pathways , 2019, Anatomical record.

[6]  C. Simopoulos,et al.  PAK1 Expression in Pancreatic Cancer: Clinicopathological Characteristics and Prognostic Significance , 2019, Clinical Medicine Insights. Oncology.

[7]  Zhou Zhu,et al.  Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer , 2019, Oncogene.

[8]  E. Reddy,et al.  Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia , 2018, Oncotarget.

[9]  C. Reis,et al.  Gastric cancer: Basic aspects , 2018, Helicobacter.

[10]  Fan Zhou,et al.  PAK1 Promotes the Proliferation and Inhibits Apoptosis of Human Spermatogonial Stem Cells via PDK1/KDR/ZNF367 and ERK1/2 and AKT Pathways , 2018, Molecular therapy. Nucleic acids.

[11]  L. Virág,et al.  Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair , 2017, Redox biology.

[12]  M. Zheng,et al.  p21-activated protein kinase 1 induces the invasion of gastric cancer cells through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase-2. , 2017, Oncology reports.

[13]  Carlos L. Arteaga,et al.  Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. , 2017, Cancer research.

[14]  H. Xi,et al.  A unified model of the hierarchical and stochastic theories of gastric cancer , 2017, British Journal of Cancer.

[15]  Y. Zavros.  Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells , 2017, Cellular and molecular gastroenterology and hepatology.

[16]  C. Pérez-Plasencia,et al.  Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition , 2016, Oncotarget.

[17]  Hue Lee,et al.  PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness , 2016, Scientific Reports.

[18]  Hongbing Shen,et al.  Potentially functional polymorphisms in PAK1 are associated with risk of lung cancer in a Chinese population , 2015, Cancer medicine.

[19]  Wei Zhao,et al.  β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation. , 2015, World journal of gastroenterology.

[20]  Liu Cao,et al.  PAK1-mediated MORC2 phosphorylation promotes gastric tumorigenesis , 2015, Oncotarget.

[21]  J. Li,et al.  PAK1 regulates RUFY3-mediated gastric cancer cell migration and invasion , 2015, Cell Death and Disease.

[22]  Peng Guo,et al.  miR-145 inhibits invasion of bladder cancer cells by targeting PAK1. , 2014, Urologic oncology.

[23]  J. Chernoff,et al.  PAK signalling during the development and progression of cancer , 2013, Nature Reviews Cancer.

[24]  Luis E. Arias-Romero,et al.  Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells. , 2013, Cancer research.

[25]  J. R. Peterson,et al.  Synergistic Activation of p21-activated Kinase 1 by Phosphatidylinositol 4,5-Bisphosphate and Rho GTPases* , 2013, The Journal of Biological Chemistry.

[26]  C. Varon,et al.  Gastric cancer: Basic aspects , 2012, Helicobacter.

[27]  J. Field,et al.  PAK signaling in cancer , 2012, Cellular logistics.

[28]  A. Ristimäki,et al.  Gastric Cancer: Basic Aspects , 2011, Helicobacter.

[29]  Theonie Anastassiadis,et al.  Phosphoinositides are essential coactivators for p21-activated kinase 1. , 2010, Molecular cell.

[30]  J. Kissil,et al.  Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. , 2010, Biochemical pharmacology.

[31]  Luis E. Arias-Romero,et al.  p21-activated kinases in ErbB2-positive breast cancer , 2010, Small GTPases.

[32]  N. Hayward,et al.  Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanoma , 2006, Melanoma research.

[33]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[34]  Hiroki Kuniyasu,et al.  Molecular diagnosis of gastric cancer: present and future , 2001, Gastric Cancer.

[35]  Wei Wu,et al.  mir-1 inhibits migration of gastric cancer cells. , 2020, Frontiers in bioscience.

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  Hanna Vauhkonen,et al.  Pathology and molecular biology of gastric cancer. , 2006, Best practice & research. Clinical gastroenterology.

[38]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.